Dexmecamylamine

Drug Profile

Dexmecamylamine

Alternative Names: Dexmecamylamine hydrochloride; NIH-11008; S(+)-mecamylamine; S-mecamylamine; TC-5214

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Targacept
  • Developer AstraZeneca; Targacept
  • Class Antidepressants; Norbornanes; Small molecules
  • Mechanism of Action Alpha3beta4 nicotinic receptor antagonists; Alpha4beta2 nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hypertension; Major depressive disorder; Overactive bladder; Resistant hypertension

Most Recent Events

  • 28 Jul 2014 Discontinued - Phase-II for Overactive bladder in USA (PO)
  • 28 Jul 2014 Top-line efficacy data from a phase IIb trial in Overactive bladder released by Targacept
  • 10 Feb 2014 Targacept completes enrolment in its phase IIb trial for Overactive bladder in USA (NCT01868516)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top